Explainer

Compounded Peptides Explained: 503A vs 503B

Compounding pharmacies occupy a distinctive space in the U.S. drug supply. They are permitted to prepare medications without going through the FDA's full drug approval process, but only within specific regulatory limits. Since 2013, the Drug Quality and Security Act (DQSA) has defined two categories of compounding — traditional pharmacies under Section 503A and outsourcing facilities under Section 503B — each with different oversight, quality requirements, and permitted activities. This page explains what each category means, how the framework applies to peptides, and why the FDA's evolving stance on bulk peptide substances matters for anyone trying to understand the compounded peptide marketplace.

Background

What Compounding Pharmacies Are and Why They Exist

Drug compounding is the process of preparing, mixing, assembling, packaging, or labeling a drug to meet an individual patient's needs. Historically, compounding was a routine pharmacy practice: pharmacists prepared medications tailored to patients who could not use a commercially manufactured product — for example, a patient who needed a liquid version of a drug sold only as a tablet, or a patient allergic to a dye or filler in a commercial product. The practice predates the modern FDA drug approval system, which was established by the 1962 Kefauver-Harris Amendment. Compounding was not eliminated by that system; instead, it persisted as a narrow exception. When the FD&C Act was originally written, compounding was assumed to be a small-scale pharmacy activity, not a manufacturing operation. The law's compounding exemptions reflect that assumption: compounded drugs are exempt from certain requirements of the drug approval process — specifically new drug approval (Section 505) and adequate directions for use labeling — provided they meet specific conditions.

Key points

• Compounding pharmacies prepare customized medications for patients who cannot use commercially manufactured products — for example, patients needing alternative dosage forms, allergen-free formulations, or products that are commercially unavailable.
• Compounded drugs are exempt from FDA new drug approval requirements, adequate directions for use labeling, and (depending on the compounding category) cGMP requirements — but only if the compounder meets the conditions specified in Sections 503A or 503B of the FD&C Act.
• The regulatory tension is that compounding was designed as a pharmacy activity for individual patients, but some compounding operations have scaled up to function more like manufacturers — producing large batches for wide distribution. The DQSA was enacted in part to address this tension.
• Before the DQSA, compounding was regulated under a patchwork of state law and FDA guidance documents, creating ambiguity about which regulatory framework applied to which activities.

Legislation

The Drug Quality and Security Act (DQSA) of 2013

The Drug Quality and Security Act (DQSA) was signed into law on November 27, 2013. It was enacted in response to the 2012 New England Compounding Center (NECC) meningitis outbreak, in which contaminated compounded steroid injections caused more than 750 infections and over 60 deaths across multiple states. The outbreak exposed the gap in the regulatory framework: NECC had been operating as a large-scale compounder distributing products across state lines without individual patient prescriptions, but it was not subject to the same manufacturing oversight as a drug manufacturer. The DQSA addressed this by creating two distinct statutory categories of compounding: Section 503A (traditional compounding pharmacies) and Section 503B (outsourcing facilities). The law also established requirements for facilities that compound sterile drugs and for compounders that produce drugs in bulk without patient-specific prescriptions.

Key points

• The DQSA was enacted in direct response to the 2012 New England Compounding Center (NECC) outbreak, where contaminated compounded injections caused dozens of deaths, exposing the inadequacy of the pre-2013 compounding regulatory framework.
• The law created two compounding categories: Section 503A for traditional pharmacies and Section 503B for outsourcing facilities, each with different requirements and levels of federal oversight.
• Section 503A codified and clarified the conditions under which traditional compounding pharmacies can compound drugs without FDA new drug approval — conditions that had previously been defined by court decisions and FDA guidance.
• Section 503B created a new category of facility — the outsourcing facility — that can compound drugs in bulk without patient-specific prescriptions, but must register with the FDA and comply with cGMP requirements.
• The DQSA also established the Pharmacy Compounding Advisory Committee (PCAC), a federal advisory committee that advises the FDA on matters related to compounding, including the evaluation of bulk drug substances.

503A

Section 503A: Traditional Compounding Pharmacies

Section 503A of the FD&C Act defines the regulatory framework for traditional compounding pharmacies. These are state-licensed pharmacies that compound medications pursuant to patient-specific prescriptions from authorized prescribers. The key distinction of 503A is the requirement for a valid patient-prescriber relationship: a 503A pharmacy compounds a specific drug for a specific patient, based on a prescription written for that patient. Section 503A pharmacies are exempt from three FDA requirements: new drug approval under Section 505, adequate directions for use labeling under Section 502(f)(1), and cGMP requirements under Section 501(a)(2)(B). In exchange for these exemptions, they must meet conditions including compounding pursuant to a valid prescription, using bulk drug substances that meet applicable USP or NF monographs, and not compounding drugs that have been withdrawn or removed from the market for safety reasons.

Key points

• 503A pharmacies compound pursuant to individual patient-specific prescriptions from authorized prescribers. They cannot compound drugs in bulk for anticipated demand without prescriptions.
• 503A pharmacies are regulated primarily by state boards of pharmacy, not by the FDA. Oversight standards — including inspection frequency, quality requirements, and sterile compounding standards — vary significantly by state.
• 503A pharmacies are exempt from FDA new drug approval, adequate directions for use labeling, and cGMP requirements. This means compounded drugs from 503A pharmacies have not been reviewed by the FDA for safety, efficacy, or manufacturing quality.
• The state-based oversight model means that the same compounded drug may be produced under different quality standards depending on which state the pharmacy is licensed in. State boards of pharmacy set their own standards for sterile compounding, facility requirements, and pharmacist training.
• 503A pharmacies must use bulk drug substances that comply with USP or NF monographs, must not compound drugs that have been withdrawn from the market for safety reasons, and must not compound essentially copies of commercially available drug products unless the prescriber determines that a variation is needed.

503B

Section 503B: Outsourcing Facilities

Section 503B of the FD&C Act created a new category of compounding facility: the outsourcing facility. An outsourcing facility is a facility that is registered with the FDA, engaged in the compounding of sterile drugs, and complies with cGMP requirements. Unlike 503A pharmacies, 503B outsourcing facilities can compound drugs in bulk without patient-specific prescriptions. This means they can produce larger batches and distribute them to hospitals, clinics, and other healthcare facilities for office stock — not just for individual patients. The trade-off is significantly more federal oversight: 503B facilities are subject to FDA registration and inspection, must comply with cGMP requirements (the same manufacturing standards that apply to drug manufacturers), must report adverse events, and must meet labeling requirements that differ from 503A pharmacies.

Key points

• 503B outsourcing facilities can compound drugs in bulk without patient-specific prescriptions, allowing them to produce larger batches for distribution to hospitals, clinics, and other healthcare facilities.
• 503B facilities must register with the FDA, are subject to FDA inspection on a risk-based schedule, and must comply with cGMP requirements — the same Current Good Manufacturing Practice standards that apply to drug manufacturers.
• 503B facilities must report adverse events to the FDA through the MedWatch program, creating an adverse-event reporting pathway that does not exist for 503A pharmacies.
• 503B facilities must label their products with specific information including a statement that the drug is compounded, the lot number, the beyond-use date, and a statement that the drug is not FDA-approved.
• The 503B category was designed to provide a higher-oversight alternative to the pre-DQSA environment where large-scale compounders operated without FDA registration or cGMP compliance. However, 503B drugs are still not FDA-approved and have not gone through the drug approval process.

Comparison

Key Differences: 503A vs 503B at a Glance

The distinction between 503A and 503B is not a minor regulatory detail — it determines the level of federal oversight, the manufacturing quality standards, whether a prescription is required, and whether adverse-event reporting is mandatory. For peptides obtained through telehealth or prescribed by a provider, understanding whether the compounding pharmacy operates under 503A or 503B provides meaningful context about the quality and oversight framework applied to the product.

Key points

• Prescriptions: 503A requires patient-specific prescriptions. 503B does not require patient-specific prescriptions and can compound for office stock at healthcare facilities.
• Oversight: 503A is regulated primarily by state boards of pharmacy. 503B is registered with the FDA, subject to FDA inspection, and regulated at the federal level.
• Manufacturing standards: 503A pharmacies are exempt from cGMP requirements (state boards set quality standards). 503B facilities must comply with cGMP requirements, the same manufacturing standards as drug manufacturers.
• Adverse-event reporting: 503A has no mandatory FDA adverse-event reporting. 503B must report adverse events through the FDA MedWatch program.
• Neither category is equivalent to FDA drug approval. Both 503A and 503B compounded drugs are not FDA-approved, have not been reviewed for safety or efficacy, and must be labeled as compounded products that are not FDA-approved.

Peptides

How This Applies to Compounded Peptides

Several peptides are commonly compounded by pharmacies and prescribed through telehealth channels. The most prominent example is compounded GLP-1 receptor agonists — semaglutide and tirzepatide. These drugs are FDA-approved under brand names (Ozempic, Wegovy for semaglutide; Mounjaro, Zepbound for tirzepatide), but demand has frequently outpaced manufacturer supply, leading to widespread compounding of these peptides by 503A and 503B facilities. Tesamorelin, an FDA-approved drug (Egrifta) for HIV-associated lipodystrophy, is also compounded by some pharmacies. Other peptides discussed in consumer and telehealth contexts — including growth hormone secretagogues and various experimental peptides — are not FDA-approved for any indication but may still be compounded if a prescriber writes a prescription and the pharmacy determines that the substance meets the requirements of 503A or 503B.

Key points

• Compounded semaglutide and tirzepatide became widespread during manufacturer supply shortages of Ozempic, Wegovy, Mounjaro, and Zepbound. When a drug is on the FDA's shortage list, the FDA has stated that it generally does not intend to take action against compounders for compounding a copy of that drug, because it serves a medical need created by the shortage.
• When the shortage is resolved and the drug is removed from the FDA shortage list, the FDA's policy is that compounders should stop compounding copies of the commercially available drug. The FDA has issued guidance on the transition period for compounded GLP-1 drugs when shortages end.
• Tesamorelin (Egrifta) is FDA-approved for reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy. Compounded versions may be prescribed when the branded product is unavailable or when a prescriber determines a specific variation is needed, but compounded tesamorelin has not been reviewed by the FDA for safety or efficacy.
• Peptides that are not FDA-approved for any indication — including many experimental peptides discussed online — may be compounded by 503A pharmacies if a prescriber writes a patient-specific prescription and the bulk drug substance is permitted for compounding. The regulatory question of which bulk substances can be used in compounding is an evolving and contested area.
• The distinction between 503A and 503B matters for peptide consumers: a peptide compounded by a 503B facility has been produced under cGMP standards and is subject to FDA inspection and adverse-event reporting, while a peptide from a 503A pharmacy depends primarily on state-level oversight.

Regulatory

The FDA's Bulk Drug Substance Evaluation and the Risk List

A central regulatory question for compounding is which bulk drug substances can be used by compounders. The FDA maintains a list of bulk drug substances that may present significant safety risks in compounding contexts. Substances on this list are ones that the FDA has evaluated and determined may pose significant safety concerns when used in compounding — either because of the substance's inherent pharmacological properties, because of the complexity of compounding with it, or because of inadequate safety data. The existence of this list does not automatically ban compounding with listed substances, but it signals the FDA's concern and can affect the regulatory risk for compounders who use them. The FDA also maintains a list of bulk drug substances that are eligible for use in compounding by 503A pharmacies (the 503A bulks list) and separately for 503B outsourcing facilities (the 503B bulks list), though both lists are still being developed.

Key points

• The FDA maintains a list of bulk drug substances that may present significant safety risks in compounding. Substances on this list are ones the FDA has identified as potentially dangerous to compound with, based on pharmacological properties, compounding complexity, or insufficient safety data.
• The 503A bulks list and 503B bulks list are being developed by the FDA through a nomination and evaluation process. Substances are nominated for inclusion, evaluated by the Pharmacy Compounding Advisory Committee (PCAC), and then the FDA makes a determination about whether to include them on the applicable list.
• A substance being on the risk list does not automatically prohibit compounding with it, but it signals the FDA's safety concern and may affect enforcement decisions and the regulatory risk for compounders.
• For peptides, the bulk substance evaluation process is particularly significant because many peptides discussed in consumer contexts are not FDA-approved for any indication and have limited human safety data. The FDA's evaluation of whether a peptide is safe to compound is a separate question from whether the peptide is effective for any indication.
• The lists are not static. The FDA periodically adds and removes substances, and the nomination and evaluation process is ongoing. The July 2026 PCAC meeting is a recent example of this process.

Advisory

The July 2026 PCAC Meeting and Its Significance for Peptides

The FDA's Pharmacy Compounding Advisory Committee (PCAC) met on July 23-24, 2026, to discuss multiple bulk drug substances nominated for use in compounding. The PCAC is a federal advisory committee that provides independent, expert advice to the FDA on compounding-related matters, including the safety and appropriateness of specific substances for use in compounding. The July 2026 meeting is significant for the peptide landscape because multiple peptide bulk substances were on the agenda for discussion. The committee's recommendations are advisory — the FDA makes the final determination — but the PCAC's evaluation influences which substances are added to or removed from the 503A and 503B bulk drug substance lists.

Key points

• The July 23-24, 2026 PCAC meeting included discussion of multiple peptide bulk substances nominated for use in compounding. The meeting agenda and materials are public records available through the FDA advisory committee website.
• Peptides like BPC-157 and TB-500, which are widely discussed in consumer and biohacking communities but are not FDA-approved for any indication, are among the substances whose compounding status is subject to FDA evaluation. The PCAC's review of such substances affects whether 503A pharmacies and 503B outsourcing facilities can compound them.
• The PCAC evaluates substances based on safety considerations — not efficacy. A substance can be evaluated as potentially safe to compound even if it has no proven clinical efficacy, and a substance can be flagged as a safety risk based on pharmacological properties, compounding complexity, or insufficient safety data.
• The committee's recommendations are advisory. The FDA considers the PCAC's input but makes the final determination about which substances to include on the 503A bulks list, the 503B bulks list, and the risk list. Final determinations may not match the committee's recommendations.
• The outcomes of the July 2026 meeting may change which peptides are available through compounding channels, which could in turn affect availability through telehealth prescribing and shift activity toward or away from the RUO marketplace.

Risk

Risks and Benefits: Compounded vs Manufactured Drugs

Compounded drugs occupy a middle ground between FDA-approved manufactured drugs and unregulated products. They are not FDA-approved, but they are produced under varying levels of regulatory oversight — from state-board supervision (503A) to FDA registration and cGMP compliance (503B). Understanding the risks and benefits of compounded drugs compared to manufactured drugs is essential for contextualizing claims about compounded peptides, evaluating quality, and interpreting the regulatory landscape.

Key points

• Benefits of compounding: Compounding can provide access to drugs that are commercially unavailable (due to shortage or discontinuation), alternative dosage forms for patients who cannot use the commercial product, allergen-free formulations, and products tailored to individual patient needs as determined by a prescriber.
• Risks of compounding: Compounded drugs are not FDA-approved and have not been reviewed for safety, efficacy, or manufacturing quality. Quality varies by pharmacy. 503A quality depends on state board oversight, which varies by state. 503B quality is higher due to cGMP compliance and FDA inspection, but still not equivalent to FDA approval.
• Manufactured drugs (FDA-approved): Go through the full FDA drug approval process — clinical trials for safety and efficacy, cGMP manufacturing, FDA inspection of facilities, labeling review, and post-market surveillance including MedWatch adverse-event reporting. This is the highest level of drug oversight in the U.S. system.
• Key quality differences: FDA-approved drugs have consistent potency, purity, sterility, and labeling verified through the approval process. Compounded drugs may vary between batches and between pharmacies. 503B facilities provide more consistency than 503A due to cGMP compliance, but neither matches the consistency of an FDA-approved product.
• Both compounded and manufactured drugs carry some risk, but the risk profile differs. Manufactured drugs have well-characterized risks documented through clinical trials and post-market surveillance. Compounded drugs may have less well-characterized risks because they have not been through the same review process — particularly for substances with limited human safety data.

Trend

The Evolving Regulatory Landscape for Compounded Peptides

The regulatory framework for compounded peptides is not static. The FDA's bulk drug substance evaluation process, PCAC meetings, enforcement actions, shortage-list changes, and the ongoing development of the 503A and 503B bulks lists all affect which peptides can be compounded, under what conditions, and with what level of oversight. The July 2026 PCAC meeting is a recent example of this ongoing process, but it is not the final word — subsequent meetings, FDA determinations, and enforcement actions may further reshape the landscape. Readers should not assume that current availability or regulatory status will remain unchanged.

Key points

• The FDA's evaluation of bulk drug substances for compounding is an ongoing process. Substances are nominated, evaluated by the PCAC, and the FDA makes determinations that can add or remove substances from the permitted lists or the risk list.
• The FDA's shortage list affects whether compounders can compound copies of commercially available drugs. When a drug is on the shortage list, compounding is generally permitted; when the shortage is resolved, the FDA expects compounders to stop compounding copies of that drug.
• The FDA's enforcement actions against sellers who market peptides outside of regulated channels — including RUO sellers who make therapeutic claims — indirectly affect the compounding landscape by clarifying which channels are and are not acceptable for peptide distribution.
• The development of the 503A and 503B bulks lists is incomplete as of 2026. Many substances are still under evaluation, and the lists may change as the FDA completes its review of nominated substances.
• Readers should verify current regulatory status rather than relying on static summaries. The FDA's compounding website, the PCAC meeting page, and the bulk drug substance risk list are public resources for checking the current state of the framework.

Related pages